<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604682</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-PSOR-001</org_study_id>
    <nct_id>NCT00604682</nct_id>
  </id_info>
  <brief_title>Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis</brief_title>
  <acronym>PSOR-001</acronym>
  <official_title>Open-Label, Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC10004 in Subjects With Severe Plaque Type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label study for patients with severe plaque type psoriasis. This study is looking to
      evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the
      epidermal thickness in subjects with severe placque type psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2005</start_date>
  <completion_date type="Actual">December 1, 2005</completion_date>
  <primary_completion_date type="Actual">October 1, 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pharmacodynamic effect of orally administered CC10004 when taken for 29 days in reducing epidermal thickness in subjects with severe plaque-type psoriasis.</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of orally administered CC10004 in subjects with severe plaque-type psoriasis during the treatment and follow up phases.</measure>
    <time_frame>58 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the clinical efficacy of orally administered CC10004 when taken for 29 days in subjects with severe plaque-type psoriasis.</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the clinical efficacy of CC10004 when taken for 29 days in subjects with psoriatic arthritis.</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Administration of CC10004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC10004</intervention_name>
    <description>2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted</description>
    <arm_group_label>Administration of CC10004</arm_group_label>
    <other_name>Apremilast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Must understand and voluntarily sign an informed consent form

          -  Must be age &gt; or = to 18 years to 65 years at the time of singing the informed consent
             form.

          -  Must be able to adhere to the study visit schedule and other protocol requirements

          -  Must have a history of severe plaque type psoriasis for at least 6 months, and at
             least a 15% affected total body surface area (BSA)

          -  Must meet the following clinical laboratory criteria:

          -  White Blood Cell Count &gt; or = to 3000/cu mm and &lt; 20,000/cu mm

          -  Platelet count &gt; or = to 100,000/microliters

          -  Serum creatinine &lt; or = to 1.5 mg/dl

          -  Total bilirubin &lt; or = to 2.0 mg/dl

          -  AST (SGOT) and ALT (SGPT) &lt; or = to 1.5 X ULN

          -  Must have a psoriatic plaque &gt; or = to 2.5 cm in diameter (for biopsy)

          -  Must be candidate for photo/systemic therapy (a subject is considered a candidate for
             photo/systemic therapy if a clinician judges that the subject requires any systemic
             therapy (e.g., ultraviolet light B(UVB), Psoralens and long-wave ultraviolet radiation
             (PUVA), cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate
             mofetil, thioguanine, hydroxyurea, sirolimus, tacrolimus, azathioprine)to control
             psoriasis whether or not that subject has a history of receiving systemic therapy)

          -  Women of child bearing potential (WCBP) must have a negative urine pregnancy test at
             Screening (Visit 1). In addition, sexually active WCBP must agree to use two forms of
             adequate forms on contraception throughout the trial.

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality , or psychiatric illness that
             would prevent the subject from signing the informed consent form

          -  Pregnant or lactating females

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study

          -  Current erythrodermic, guttate, or pustular psoriasis

          -  Use of medication that is metabolized by the CYP3A4 or CYP2A6 pathways within the 14
             days of study medication initiation and/or required use of such medication during
             study treatment.

          -  Drinking or ingesting grapefruits, grapefruit juice or grapefruit containing products
             within 14 days of study medication initiation

          -  Use of topical therapy ( topical steroids, topical vitamin A or D analog preparations,
             tacrolimus, pimecrolimus, or anthralin) within 14 days of study medications initiation
             (Exception: Non-medicated emollients and tar shampoo will be allowed)

          -  Use of systemic therapy for psoriasis

          -  Use or phototherapy within 28 days of study medication initiation

          -  Use Humira or Remicade within 3 months of study medication initiation

          -  Use of Enbrel within 56 days of study medication initiation

          -  Use of Raptiva within 56 days of study medication initiation

          -  Use of Amevive within 6 months of study medication initiation

          -  Use of any investigational drug within 30 days of study medication initiation or 5
             half lives if known

          -  History of clinically significant cardiac, endocrinologic, pulmonary, neurologic,
             psychiatric, hepatic, renal, hematologic, immunologic insufficiency disease or other
             major diseases

          -  Clinically significant abnormality on 12-lead ECG at screening

          -  Positive HIV, Hepatitis B or Hepatitis C laboratory result at screening

          -  History of active tuberculosis within previous 3 years

          -  Clinically significant abnormality on the chest x-ray at screening or on CXR taken
             within 6 months of screening

          -  History of positive purified protein derivative (PPD) test at screening

          -  History of malignancy within previous five years

          -  Evidence of skin conditions at the time of screening visit other than psoriasis that
             would interfere with evaluations of the effect of study medication on psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Rohane, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/clinical-study-report-csr-synopses/purposes-of-posting-clinical-study-report-csr-synopses</url>
    <description>Link to CSR synopsis</description>
  </link>
  <reference>
    <citation>Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008 May;24(5):1529-38. doi: 10.1185/030079908X301866 . Epub 2008 Apr 16.</citation>
    <PMID>18419879</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

